{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:33:26Z","timestamp":1778855606156,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1053\/j.ackd.2014.01.005","type":"journal-article","created":{"date-parts":[[2014,3,3]],"date-time":"2014-03-03T23:01:37Z","timestamp":1393887697000},"page":"166-181","source":"Crossref","is-referenced-by-count":7,"title":["B Cell Suppression in Primary Glomerular Disease"],"prefix":"10.1053","volume":"21","author":[{"given":"Ilse M.","family":"Rood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia M.","family":"Hofstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen K.J.","family":"Deegens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack F.M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.ackd.2014.01.005_bib1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0272-6386(00)70258-7","article-title":"Changing incidence of glomerular diseases in adults","volume":"35","author":"Braden","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.005_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJMe0903343","article-title":"Human idiopathic membranous nephropathy\u2013a mystery solved?","volume":"361","author":"Glassock","year":"2009","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1053\/j.ackd.2014.01.005_bib3","first-page":"64","article-title":"Secondary membranous glomerulonephritis","volume":"7","author":"Glassock","year":"1992","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.005_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ackd.2014.01.005_bib5","first-page":"109","article-title":"Anti-PLA(2)R antibodies in membranous nephropathy: ready for routine clinical practice?","volume":"70","author":"Hofstra","year":"2012","journal-title":"Neth J Med"},{"issue":"9","key":"10.1053\/j.ackd.2014.01.005_bib6","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2215\/CJN.02170312","article-title":"Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy","volume":"7","author":"Murtas","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2014.01.005_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000185325","article-title":"Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome","volume":"51","author":"Yoshizawa","year":"1989","journal-title":"Nephron"},{"issue":"8","key":"10.1053\/j.ackd.2014.01.005_bib8","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med"},{"issue":"7","key":"10.1053\/j.ackd.2014.01.005_bib9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","article-title":"Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy","volume":"19","author":"Benz","year":"2004","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1053\/j.ackd.2014.01.005_bib10","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1007\/s00467-005-2013-7","article-title":"Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome","volume":"20","author":"Nozu","year":"2005","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.005_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clim.2006.08.016","article-title":"Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE","volume":"122","author":"Vallerskog","year":"2007","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.005_bib12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2215\/CJN.04580709","article-title":"Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases","volume":"5","author":"Vincenti","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.005_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/kisup.2012.9","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"11","key":"10.1053\/j.ackd.2014.01.005_bib14","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/ndt\/gfn350","article-title":"Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands","volume":"23","author":"Hofstra","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ackd.2014.01.005_bib15","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/ndt\/gfq017","article-title":"Alkylating agents in membranous nephropathy: efficacy proven beyond doubt","volume":"25","author":"Hofstra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.005_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1681\/ASN.2013020185","article-title":"Long term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy","volume":"25","author":"Van den Brand","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2014.01.005_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrneph.2013.125","article-title":"Treatment of idiopathic membranous nephropathy","volume":"9","author":"Hofstra","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"9337","key":"10.1053\/j.ackd.2014.01.005_bib18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.ackd.2014.01.005_bib19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2215\/CJN.01080905","article-title":"Rituximab for idiopathic membranous nephropathy: who can benefit?","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2014.01.005_bib20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.005_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of\u00a0idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ackd.2014.01.005_bib22","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2014.01.005_bib23","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2014.01.005_bib24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2215\/CJN.06041108","article-title":"Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients","volume":"4","author":"Segarra","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2014.01.005_bib25","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.005_bib26","unstructured":"ClinicialTrials.gov: A service of the U.S. National Institutes of Health. Available at: www.clinicaltrials.gov. Accessed: July 1, 2013."},{"issue":"7","key":"10.1053\/j.ackd.2014.01.005_bib27","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1053\/j.ackd.2014.01.005_bib28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1081\/JDI-100101955","article-title":"The role of podocyte injury in the pathogenesis of focal segmental glomerulosclerosis","volume":"22","author":"Schwartz","year":"2000","journal-title":"Ren Fail"},{"issue":"2","key":"10.1053\/j.ackd.2014.01.005_bib29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1053\/j.ajkd.2003.10.024","article-title":"Pathologic classification of focal segmental glomerulosclerosis: a working proposal","volume":"43","author":"D'Agati","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ackd.2014.01.005_bib30","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/ki.2011.191","article-title":"Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial","volume":"80","author":"Deegens","year":"2011","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ackd.2014.01.005_bib31","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","article-title":"Rituximab in refractory nephrotic syndrome","volume":"25","author":"Prytula","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"10.1053\/j.ackd.2014.01.005_bib32","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00467-011-1886-x","article-title":"Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome","volume":"26","author":"Ito","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1053\/j.ackd.2014.01.005_bib33","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2215\/CJN.03470410","article-title":"Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report","volume":"5","author":"Gulati","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2014.01.005_bib34","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","article-title":"Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome","volume":"27","author":"Kemper","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ackd.2014.01.005_bib35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","article-title":"Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome","volume":"28","author":"Ito","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2014.01.005_bib36","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00467-012-2406-3","article-title":"Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome","volume":"28","author":"Tellier","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"11-12","key":"10.1053\/j.ackd.2014.01.005_bib37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00508-013-0366-7","article-title":"Rituximab in adult patients with multi-relapsing\/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases","volume":"125","author":"Kronbichler","year":"2013","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"10.1053\/j.ackd.2014.01.005_bib38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","article-title":"Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease","volume":"83","author":"Munyentwali","year":"2013","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2014.01.005_bib39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00467-011-1997-4","article-title":"Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome","volume":"27","author":"Sinha","year":"2012","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"10.1053\/j.ackd.2014.01.005_bib40","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","article-title":"Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children","volume":"24","author":"Kamei","year":"2009","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2014.01.005_bib41","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00467-009-1377-5","article-title":"Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine","volume":"25","author":"Fujinaga","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"10.1053\/j.ackd.2014.01.005_bib42","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2215\/CJN.05691108","article-title":"Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children","volume":"4","author":"Kyrieleis","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2014.01.005_bib43","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ki.2013.211","article-title":"Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome","volume":"84","author":"Ravani","year":"2013","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ackd.2014.01.005_bib44","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","article-title":"Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood\u2013follow-up after CD19 recovery","volume":"27","author":"Sellier-Leclerc","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ackd.2014.01.005_bib45","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","article-title":"Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults","volume":"28","author":"Takei","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ackd.2014.01.005_bib46","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Ravani","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2014.01.005_bib47","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00467-011-1778-0","article-title":"Rituximab for refractory cases of childhood nephrotic syndrome","volume":"26","author":"Kari","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2014.01.005_bib48","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s004670050167","article-title":"Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children","volume":"10","author":"Tarshish","year":"1996","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2014.01.005_bib49","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1681\/ASN.2011080775","article-title":"Rituximab in children with resistant idiopathic nephrotic syndrome","volume":"23","author":"Magnasco","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2014.01.005_bib50","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2215\/CJN.00570109","article-title":"Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis","volume":"4","author":"Fernandez-Fresnedo","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"26","key":"10.1053\/j.ackd.2014.01.005_bib51","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1056\/NEJMc063706","article-title":"Rituximab in patients with the steroid-resistant nephrotic syndrome","volume":"356","author":"Bagga","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.005_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2369-14-47","article-title":"A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation","volume":"14","author":"Maas","year":"2013","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.005_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/ndt\/gfp538","article-title":"Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation","volume":"25","author":"Ponticelli","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2014.01.005_bib54","doi-asserted-by":"crossref","first-page":"374213","DOI":"10.1155\/2011\/374213","article-title":"The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review","volume":"2011","author":"Araya","year":"2011","journal-title":"J Transplant"},{"issue":"2","key":"10.1053\/j.ackd.2014.01.005_bib55","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00467-012-2314-6","article-title":"Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis","volume":"28","author":"Kumar","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2014.01.005_bib56","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","article-title":"Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases","volume":"23","author":"Guigonis","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2014.01.005_bib57","doi-asserted-by":"crossref","first-page":"R161","DOI":"10.1186\/ar3901","article-title":"B lymphocyte-typing for prediction of clinical response to rituximab","volume":"14","author":"Brezinschek","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1053\/j.ackd.2014.01.005_bib58","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","article-title":"Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response","volume":"47","author":"Breedveld","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1053\/j.ackd.2014.01.005_bib59","doi-asserted-by":"crossref","first-page":"c98","DOI":"10.1159\/000319656","article-title":"Effect of single-dose rituximab on primary glomerular diseases","volume":"117","author":"Sugiura","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"10.1053\/j.ackd.2014.01.005_bib60","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5414\/CN107299","article-title":"Rituximab therapy for Type I membranoproliferative glomerulonephritis","volume":"77","author":"Dillon","year":"2012","journal-title":"Clin Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2014.01.005_bib61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5414\/CN107092","article-title":"Rituximab in adult patients with immunosuppressive-dependent minimal change disease","volume":"76","author":"Hoxha","year":"2011","journal-title":"Clin Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2014.01.005_bib62","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1525-1594.2010.01068.x","article-title":"Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation","volume":"35","author":"Tsagalis","year":"2011","journal-title":"Artif Organs"},{"issue":"5","key":"10.1053\/j.ackd.2014.01.005_bib63","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1111\/j.1432-2277.2012.01462.x","article-title":"Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after\u00a0a second renal transplantation","volume":"25","author":"Audard","year":"2012","journal-title":"Transpl Int"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559514000081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559514000081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T03:25:40Z","timestamp":1538796340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559514000081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1548559514000081"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2014.01.005","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}